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We read with great interest the article about the 
comparison for 3 kinds of toxin enzyme immunoassay (EIA) 
as a screening test by Reller and colleagues.1 As described 
in the article, EIA for toxin A and toxin B has been widely 
used for the diagnosis of Clostridium difficile infection 
owing to its simplicity and short turnaround time.2 However, 
although the sensitivity of EIA has been reported to be 
improved in dry and wet tests, problems associated with its 
relatively low sensitivity still have been reported, and many 
large laboratories are now replacing or keeping pace with 
polymerase chain reaction (PCR)-based methods. Therefore, 
in a study we planned to compare the most popular 2 
methods for detecting C difficile, EIA and real-time PCR.
This study was conducted at Kyung Hee University 
Hospital, a tertiary teaching hospital in Seoul, Korea, from 
October 2010 to February 2011, using 291 fresh diarrheal 
stools. All specimens were immediately tested by culture and 
VIDAS C difficile toxins A & B assay using an automated 
VIDAS immunoanalyzer (bioMérieux, Marcy l’Etoile, 
France), and the remainder was stored at –70°C until 
required for real-time PCR. The alcohol shock procedure was 
performed to improve the sensitivity of anaerobic culture.3 
Aliquots were directly inoculated on C difficile selective agar 
(CDSA, Becton Dickinson, Sparks, MD) and blood agar 
(BAP) plates and incubated in an anaerobic jar for 48 to 72 
hours at 35°C.2 A Rapid ID 32 A test (bioMérieux, La Balme 
les Grottes, France) was used for identification of the species 
of the colonies on plates. Real-time PCR for toxin genes 
was performed by first preparing DNA using a QIAamp 
mini stool kit (Qiagen, Hilden, Germany). Real-time PCR 
was performed according to the manufacturer’s instructions 
(AdvanSure CD real-time PCR kit, LG Lifesciences, Seoul, 
Korea) with the SLAN real-time PCR detection system (LG 
Lifesciences). An in-house PCR test for toxin A, toxin B, and 
binary toxin was performed as described previously.4
Of 291 clinical samples, 266 showed identical results 
between EIA and real-time PCR assays, and the concordance 
rate was 91.4%. To resolve discrepancies, we performed our 
in-house PCR assay on colonies from a total of 30 culture-
positive samples. In-house PCR for toxin A and toxin B 
detected another 5 positive samples, while repeated real-time 
PCR assays of these specimens remained negative. However, 
when real-time PCR was performed using cultured colonies, 
all 5 specimens were positive. These changes may have 
been due to differences in the amount of bacteria between 
the original stool specimens and cultured colonies or the 
presence of PCR inhibitors in stools.
Feces contain various PCR inhibitors, such as bilirubin, 
excessive metal cations, and phytic acid.5 These PCR 
inhibitors may result in false-negatives; however, since 
the internal control was positive, this seems unlikely. Two 
previous studies have evaluated repeated PCR testing for 
toxin genes, and they reported a few cases that became 
positive when serial specimens were tested.6,7 These results 
suggest that the amount of bacteria in a specimen may 
influence the results of PCR assays.
A partially deleted toxin A gene was found in 3 
specimens and resulted in approximately 700-base-pair bands 
after amplification by in-house PCR. These partially deleted 
toxin A genes were not detected by real-time PCR for the 
toxin A gene; therefore, positive EIA on these specimens 
may be due to the detection of toxin B. The binary toxin gene 
was identified in only 2 strains, while no ribotype 027 was 
detected. Finally, 10 specimens resulted in false-negative 
EIA results, while another 5 specimens resulted in false-
negative real-time PCR results.
To ensure detection of toxigenic C difficile strains, 
some other confirmatory method should be applied to 
indeterminate clinical specimens. Moreover, repeating PCR 
tests on cultured colonies might increase the sensitivity of 
PCR-based methods.
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laboratory professionals because toxigenic culture is labor-
intensive and costly, particularly when added to the cost of 
molecular testing.
Finally, we read with interest the authors’ study compar-
ing PCR with EIA, since we are not aware of any study to 
date that demonstrates equivalence between the 2 diagnostic 
approaches. We applaud the authors for additionally perform-
ing toxigenic culture on all stool specimens in their study and 
would be interested in full (n = 291) reporting of the diagnos-
tic performance (sensitivity, specificity, positive predictive 
value, and negative predictive value) of EIA and real-time 
PCR relative to that gold standard.
Megan E. Reller, MD, PhD, MPH
Karen C. Carroll, MD
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Johns Hopkins Medical Institutions
Baltimore, MD
The Authors’ Reply
We appreciate the interest of Cho and colleagues in our 
article.1 We agree that EIAs for toxin are insensitive for the 
diagnosis of toxigenic C difficile and that molecular detec-
tion of toxin in stool is more sensitive than EIAs used alone 
or as part of 2- or 3-step algorithms that include cell culture 
cytotoxicity neutralization assays (CCNAs).1,2 In addition, 
several molecular tests have been well-evaluated and are ap-
proved by the US Food and Drug Administration. However, 
molecular assays have not been shown to be more sensitive 
than culture. Therefore, toxigenic culture is the gold standard 
to which new assays should be compared, a point highlighted 
in the IDSA/SHEA guidelines for diagnostic testing for C 
difficile infection.3 Hence, culturing stool for C difficile and 
confirming toxin production by performing PCR on cultured 
colonies is reasonable in selected cases in which other testing 
(EIA + CCNA or PCR on stool) is negative and high clinical 
suspicion of C difficile infection remains. We would em-
phasize the need for communication between clinicians and 
Heejung Kim, MD
Department of Laboratory Medicine
Yonsei University Yongin Severance Hospital
Yongin, Korea
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